(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 8.18% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Cytek Biosciences's revenue in 2026 is $196,828,000.On average, 6 Wall Street analysts forecast CTKB's revenue for 2026 to be $26,990,986,965, with the lowest CTKB revenue forecast at $25,688,044,347, and the highest CTKB revenue forecast at $28,166,064,752. On average, 6 Wall Street analysts forecast CTKB's revenue for 2027 to be $29,270,816,884, with the lowest CTKB revenue forecast at $26,904,038,880, and the highest CTKB revenue forecast at $30,693,952,442.
In 2028, CTKB is forecast to generate $31,941,913,182 in revenue, with the lowest revenue forecast at $29,447,270,349 and the highest revenue forecast at $33,632,286,235.